Murphy & Mullick Capital Management Corp Verve Therapeutics, Inc. Transaction History
Murphy & Mullick Capital Management Corp
- $103 Billion
- Q1 2025
A detailed history of Murphy & Mullick Capital Management Corp transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Murphy & Mullick Capital Management Corp holds 43 shares of VERV stock, worth $478. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43
Previous 43
-0.0%
Holding current value
$478
Previous $243,000
18.93%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
199Shares Held
82.4MCall Options Held
233KPut Options Held
186K-
Alphabet Inc. Mountain View, CA12.2MShares$135 Million8.86% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$76.8 Million1.39% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$73.7 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$44.5 Million2.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$44 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $667M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...